BioMarin to Provide Updated Data for BMN 270 in Hemophilia A in Late Breaking Oral Presentation at the World Federation of He...
July 21 2016 - 4:03PM
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that
interim results of an open-label, Phase 1/2 study of BMN 270, an
AAV5-FVIII Gene transfer in severe Hemophilia will be presented at
the XXXII International Congress of the World Federation of
Hemophilia. BMN 270 has received orphan drug designation from
the European Commission and U.S. Food and Drug
Administration. BioMarin management to hold conference call and
webcast to discuss the data on Wednesday, July 27, at 4:05pm ET.
The data will be presented in the Late Breaking
Gene Therapy session between 2:15pm-3:45pm ET in Room Hall A 4 by
John Pasi, Professor of Haemostasis and Thrombosis, Barts and the
London School of Medicine, Honorary Consultant Haematologist, The
Royal London Hospital, a lead investigator on the study. The
data presented at the WFH congress will be updated since the
Company reported preliminary data April 20, 2016.
Conference Call to be Held Wednesday, July 27th at
4:05pm ET
Interested parties may access a live webcast of
the conference call via the investor section of the BioMarin
website, www.biomarin.com. The Late Breaker slide presentation
will be available to download in advance of the call. A
replay of the will be archived on the site for one week following
the call.
U.S. / Canada Dial-in Number: (866) 502-9859 International
Dial-in Number: (574) 990-1362 Conference ID: 52603053
Replay Dial-in Number: (855) 859-2056 Replay International
Dial-in Number: (404) 537-3406 Conference ID: 52603053
About BioMarin
BioMarin is a global biotechnology company that
develops and commercializes innovative therapies for patients with
serious and life-threatening rare and ultra-rare genetic diseases.
The company's portfolio consists of five commercialized products
and multiple clinical and pre-clinical product candidates. For
additional information, please
visit www.biomarin.com.
Contacts:
Investors
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558
Media
Debra Charlesworth
BioMarin Pharmaceutical Inc.
(415) 455-7451
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024